Active Pharmaceutical Ingredients
Product Name
CAS Number
Specification
DMF
CEP
Status
CN
PV
(Ruxolitinib phosphate)
941678-49-5&1092939-17-7
In-house
√
A
(琥珀酸)瑞波西利
1211441-98-3 & 1374639-75-4
In-house
Q4 2026
Tepotinib
1946826-82-9
In-house
Q1 2027
Ivacaftor
873054-44-5
In-house
√
Sodium Sulfadiazine
163253-35-8
203787-91-1
√
Tofacitinib Citrate
540737-29-9
In-house
√
A
Perfluorohexane
133331-77-8
In-house
Q4 2026
Bimatoprost
155206-00-1
In-house
√
I
Cabozantinib
849217-68-1
In-house
√
Bemimetinib
606143-89-9
In-house
√
I
Ibrutinib
936563-96-1
In-house
√
I
Trametinib
871700-17-3
In-house
√
I
Venetoclax
1257044-40-8
√
Bulver peptide
2012558-47-1
Q2 2027
Q2 2027 Q4 2027
Enlyxipide Decanoate
2861205-06-1
Q3 2027
Q1 2028
Etacapine Hydrochloride
1334237-71-6
Q4 2026
Completed
Icobilactone hydrochloride
2763602-16-8
Q1 2027
Q3 2027
Inosine sodium
1639324-58-5
Q2 2027
Q4 2027
Lanreotide acetate
127984-74-1
Completed
Q1 2027
Semaglutide
1504602-49-6
Q4 2026
Q2 2027